We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Cumberland Pharmaceuticals (CPIX - Free Report) closed the most recent trading day at $6.25, moving +0.32% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.01%, while the tech-heavy Nasdaq lost 0.26%.
Coming into today, shares of the pharmaceutical company had gained 1.65% in the past month. In that same time, the Medical sector lost 4.12%, while the S&P 500 lost 0.19%.
Investors will be hoping for strength from CPIX as it approaches its next earnings release, which is expected to be May 14, 2019. On that day, CPIX is projected to report earnings of -$0.11 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, our latest consensus estimate is calling for revenue of $10.70 million, up 24.56% from the prior-year quarter.
CPIX's full-year Zacks Consensus Estimates are calling for earnings of -$0.24 per share and revenue of $50.11 million. These results would represent year-over-year changes of -700% and +22.99%, respectively.
Investors might also notice recent changes to analyst estimates for CPIX. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CPIX is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know
Cumberland Pharmaceuticals (CPIX - Free Report) closed the most recent trading day at $6.25, moving +0.32% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.16%. Elsewhere, the Dow gained 0.01%, while the tech-heavy Nasdaq lost 0.26%.
Coming into today, shares of the pharmaceutical company had gained 1.65% in the past month. In that same time, the Medical sector lost 4.12%, while the S&P 500 lost 0.19%.
Investors will be hoping for strength from CPIX as it approaches its next earnings release, which is expected to be May 14, 2019. On that day, CPIX is projected to report earnings of -$0.11 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, our latest consensus estimate is calling for revenue of $10.70 million, up 24.56% from the prior-year quarter.
CPIX's full-year Zacks Consensus Estimates are calling for earnings of -$0.24 per share and revenue of $50.11 million. These results would represent year-over-year changes of -700% and +22.99%, respectively.
Investors might also notice recent changes to analyst estimates for CPIX. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CPIX is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.